Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PENNISI, Grazia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.733
AS - Asia 2.275
EU - Europa 2.217
SA - Sud America 379
AF - Africa 66
OC - Oceania 9
Totale 7.679
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.656
RU - Federazione Russa 825
SG - Singapore 764
IT - Italia 579
CN - Cina 504
BR - Brasile 295
HK - Hong Kong 262
VN - Vietnam 248
DE - Germania 171
PL - Polonia 166
BD - Bangladesh 141
FR - Francia 115
FI - Finlandia 87
GB - Regno Unito 80
IN - India 74
JP - Giappone 68
NL - Olanda 45
AR - Argentina 40
CA - Canada 40
AT - Austria 35
KR - Corea 27
MX - Messico 23
TR - Turchia 23
IQ - Iraq 21
ZA - Sudafrica 21
ES - Italia 19
IR - Iran 17
SE - Svezia 17
ID - Indonesia 16
IE - Irlanda 15
SA - Arabia Saudita 14
RO - Romania 13
BE - Belgio 12
PH - Filippine 11
PY - Paraguay 11
UZ - Uzbekistan 11
EG - Egitto 10
PK - Pakistan 10
UA - Ucraina 10
AU - Australia 9
MA - Marocco 9
MY - Malesia 9
AE - Emirati Arabi Uniti 8
EC - Ecuador 8
CI - Costa d'Avorio 7
JO - Giordania 6
VE - Venezuela 6
AZ - Azerbaigian 5
CZ - Repubblica Ceca 5
GE - Georgia 5
IL - Israele 5
JM - Giamaica 5
LT - Lituania 5
TN - Tunisia 5
BO - Bolivia 4
CH - Svizzera 4
CL - Cile 4
DZ - Algeria 4
NP - Nepal 4
PE - Perù 4
TH - Thailandia 4
AL - Albania 3
GY - Guiana 3
KE - Kenya 3
KZ - Kazakistan 3
LB - Libano 3
QA - Qatar 3
SN - Senegal 3
UY - Uruguay 3
CR - Costa Rica 2
DK - Danimarca 2
GT - Guatemala 2
MT - Malta 2
PS - Palestinian Territory 2
AM - Armenia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BY - Bielorussia 1
CO - Colombia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GI - Gibilterra 1
HN - Honduras 1
HU - Ungheria 1
KG - Kirghizistan 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
RS - Serbia 1
SI - Slovenia 1
TT - Trinidad e Tobago 1
ZW - Zimbabwe 1
Totale 7.679
Salva come PNG Salva come JPEG
Città #
Singapore 487
Ashburn 439
San Jose 303
Hong Kong 229
Chandler 170
Moscow 147
Zgierz 143
Palermo 122
Fairfield 115
New York 105
Beijing 90
Los Angeles 89
Ho Chi Minh City 86
Hefei 76
Lauterbourg 68
Ann Arbor 63
Rome 63
Tokyo 63
Hanoi 62
Woodbridge 60
Santa Clara 59
Dallas 56
The Dalles 53
Helsinki 47
Houston 46
Seattle 44
Frankfurt am Main 41
Council Bluffs 39
Wilmington 38
Lappeenranta 35
Nuremberg 34
Chicago 32
Cambridge 31
São Paulo 31
Medford 29
Central 26
Altamura 25
Buffalo 25
Des Moines 24
Ludwigshafen am Rhein 21
Milan 21
Princeton 21
London 20
Orem 20
San Diego 20
Brooklyn 19
Chennai 19
Lawrence 19
Warsaw 19
Amsterdam 15
Denver 15
Dublin 15
Secaucus 14
Da Nang 13
Johannesburg 13
Paris 13
Shanghai 13
Atlanta 12
Boardman 12
Haiphong 12
Columbus 11
Guangzhou 11
Montreal 11
Washington 11
Brussels 10
Dhaka 10
Redondo Beach 10
Tashkent 10
Gallarate 9
Memphis 9
Ankara 8
Hangzhou 8
Mexico City 8
Mumbai 8
Newark 8
Riyadh 8
San Paolo di Civitate 8
Seoul 8
Vienna 8
Abidjan 7
Baghdad 7
Bari 7
Porto Alegre 7
Querétaro 7
Aragona 6
Belo Horizonte 6
Boston 6
Brasília 6
Bremen 6
City of London 6
Manchester 6
Mussomeli 6
Nashville 6
Pune 6
Rio de Janeiro 6
Riverside 6
Stockholm 6
Surabaya 6
Toronto 6
Xi'an 6
Totale 4.346
Salva come PNG Salva come JPEG
Nome #
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 295
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? 259
MAFLD: a multisystem disease 240
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 210
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives 190
Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population 186
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives 179
IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON CARDIOVASCULAR RISK IN A GENERAL POPULATION 175
IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON CARDIOVASCULAR RISK IN A GENERAL POPULATION 165
Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis 164
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD 157
Biochemical biomarkers of NAFLD/NASH 156
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach? 156
A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease 150
Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease 148
The PD-1/PD-L1 Axis in the Biology of MASLD 145
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 143
Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease 140
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes 137
Corrigendum to “SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease” [J Hepatol 80 (2024) 10-19, (S0168827823051474), (10.1016/j.jhep.2023.09.020)] 134
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis 132
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies 129
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 127
Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease 126
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease 126
Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease? 125
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies 124
Correction to: Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women (Nature Medicine, (2023), 29, 10, (2643-2655), 10.1038/s41591-023-02553-8) 124
Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria 120
Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis 118
PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease 116
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis 112
acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study 110
Point-of-Care Noninvasive Prediction of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease 109
Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis 109
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) 106
Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin-22, interleukin-6 and interleukin-1Ra concentrations according to portal hypertension and disease severity 105
SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease 105
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis 104
Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease 101
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease 98
Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease 96
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease 96
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease 96
Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility 95
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease 95
Performance of ultrasound-guided attenuation parameter and 2D shear wave elastography in patients with metabolic dysfunction-associated steatotic liver disease 94
PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD 94
Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease 82
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease 82
ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization 81
A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort Study 77
Impact of first and further decompensation in patients with compensated ACLD due to MASLD 75
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD 75
Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD 74
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study 67
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis 65
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease 65
Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C 63
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis 61
Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD 61
THE ROLE OF TRANSIENT ELASTOGRAPHY IN NAFLD 60
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women 56
Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome 55
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease 54
Key Predictors of Relevant Weight Loss in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease 50
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing betaoxidation 50
Sodium–Glucose Cotransporter 2 Inhibitor Use and Risk of Liver-Related Events in Patients With Type 2 Diabetes: A Meta-analysis of Observational Cohort Studies 50
From “Burnt-Out” to “Burning-Out”: Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction–Associated Steatotic Liver Disease From a Dynamic Perspective 46
GLP-1 receptor agonists and MASLD in diabetes: A promising path? 45
Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study 44
PNPLA3 I148M and Hepatocellular Carcinoma 43
null 6
null 6
null 3
null 3
Totale 8.120
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.374
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.374
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 0 0 0 0 0 0 0 19
2021/2022286 12 26 22 11 6 10 7 48 25 33 36 50
2022/2023594 35 92 4 71 53 68 31 92 70 7 44 27
2023/2024433 18 36 25 33 31 130 44 10 10 28 20 48
2024/20251.410 28 54 137 137 67 78 131 83 95 172 183 245
2025/20264.946 337 138 334 422 567 730 670 594 396 326 419 13
Totale 8.120